DK · antibody-drug conjugates · biotech · cancer
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series C · Apr 2026 · $75M
Jeito Capital lead, Bpifrance, RA Capital Management, Orbimed, Novo Holdings, EIFO, Vida Ventures
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.